BioCentury | Jun 15, 2018
Clinical News
Vical discontinuing HSV-2 program after Phase II miss
...that were both clinically and virologically confirmed during a minimum of nine months of surveillance. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...
...trial to treat invasive aspergillosis, which could support a limited use indication approval from FDA. Vical...
...Product (QIDP), Orphan Drug and Fast Track designations in the U.S. to treat invasive aspergillosis. Vical...